FDA warns on Endo direct mail pieces

Share this article:

The FDA fired off a warning letter to Endo Pharmaceuticals asking the company to halt distribution of two direct mail pieces for its Lidoderm pain patch because they contained unsupported claims and omitted certain risks associated with the patch.
The materials "are false or misleading because they make unsubstantiated effectiveness claims for Lidoderm, they omit and minimize serious risk information associated with the use of the drug and they inadequately communicate an important limitation in Lidoderm's approved indication," the FDA letter said.
The sales materials were sent to doctors in late 2004 and early 2005. An Endo spokesman said in a published report that the company was working with the FDA to take corrective action.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.